ProQR Therapeutics (PRQR) Invested Capital (2013 - 2026)

ProQR Therapeutics has reported Invested Capital for 14 years, with the latest figure at $5.8 million in Q1 2026.

• Quarterly Invested Capital rose 18.23% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (up 5.46% YoY) and the FY2025 annual result came in at $12.9 million, down 4.36% from the prior year.
• Invested Capital declined to $5.8 million in Q1 2026 per PRQR's latest filing, from $12.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $50.2 million in Q1 2022 and troughed at $3.1 million in Q3 2023.
• A 5-year average of $11.8 million and a median of $5.4 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2023: Invested Capital jumped 252224.18% in 2022, then plunged 91.66% in 2023.
• Over 5 years, Invested Capital stood at $15.5 million in 2022, then increased by 7.14% to $16.6 million in 2023, then slipped by 18.74% to $13.5 million in 2024, then decreased by 4.36% to $12.9 million in 2025, then sank by 55.16% to $5.8 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $5.8 million, $12.9 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.